Pulmatrix Reports Improved Losses Amid Revenue Decline and Merger Uncertainties

Pulmatrix, Inc. (NASDAQ: PULM) is a biopharmaceutical company focused on developing inhaled therapeutic products for migraine and respiratory diseases using its patented iSPERSE™ technology. As of June 30, 2025, the company reported several key financial metrics.

• Revenues: No revenue reported for Q2 2025, compared to $1.55 million in Q2 2024. This decline is attributed to the completion of the PUR1900 Phase 2b clinical trial.
• Operating Expenses: Total operating expenses decreased to $1.55 million in Q2 2025 from $7.45 million in Q2 2024, highlighting successful cost management following strategic changes, including the MannKind transaction.
• Net Loss: Net loss improved to $1.55 million in Q2 2025 from a loss of $5.81 million in the prior year. The reduced loss indicates enhanced operational efficiency.
• Cash Position: The company had $5.83 million in cash and equivalents as of June 30, 2025, down from $9.53 million at the start of the period, reflecting ongoing operational expenses.
• Accumulated Deficit: The accumulated deficit reached $300.5 million, primarily due to historical losses from R&D and operational expenditures.
• Merger with Cullgen Inc.: On November 13, 2024, Pulmatrix entered into a merger agreement with Cullgen, which was approved by stockholders on June 16, 2025. The closing of the merger is pending various regulatory approvals, including from the China Security Regulatory Commission.

Positive Aspects:

• Significant reduction in operating expenses indicates management's effective cost-control measures following the strategic restructuring.
• Improvement in net loss positions reflects better operational efficiency.

Negative Aspects:

• Complete absence of revenue in 2025 raises concerns about the company's ability to generate sales post-trial completion.
• Dependence on the success of the Cullgen merger poses risks if not finalized as regulatory hurdles remain.
• The company's accumulated deficit suggests ongoing financial distress, requiring additional funding for future operations and product developments.

In summary, while Pulmatrix shows signs of improving operational efficiencies, it faces substantial revenue challenges and uncertainties surrounding its merger process that could impact its financial stability.